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Analysis of Clinical Outcomes and Cost-Effectiveness of Neuromuscular Blocking Drug
Reversal in Patients with Obstructive Sleep Apnea
Abstract
Non-depolarizing neuromuscular blockers are used during many surgical procedures to
induce muscle relaxation for tracheal intubation and improve surgical conditions for surgeons.
The use of these medications requires an agent to be given to fully reverse the effects of the
neuromuscular blocking drug. Historically, neostigmine has widely been used as the primary
reversal agent. However, sugammadex, a recently FDA approved drug, is also available for the
reversal of common neuromuscular blocking drugs, rocuronium and vecuronium. In the
literature, sugammadex is widely regarded as a clinically superior reversal agent. But its use is
commonly limited to emergent situations due to the high price associated with the drug. A risk
associated with reversal agents is incomplete recovery from the neuromuscular blockade that can
lead to postoperative pulmonary complications. Patients with certain comorbidities are at higher
risk for postoperative pulmonary complications (PPCs). Patients with obstructive sleep apnea
already struggle with airway obstruction and may be at higher risk for adverse outcomes after the
use of neuromuscular blocking agents (NMBAs). Therefore, this project seeks to provide
evidence-based recommendations for NMBA reversal in patients diagnosed with or identified as
at risk for OSA through a literature search and synthesis. Therefore, the project developed
evidence-based practice recommendations utilizing the John Hopkins Nursing Evidence-Based
Practice Model by asking a practice question, evaluating, and translating findings into practice.
The project will also outline a plan for implementation and evaluation of outcomes such as cost
effectiveness and clinical outcomes.
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Problem Identification
Introduction of Problem
Neuromuscular blocking agents (NMBAs) are an essential part of anesthesia care and
management in the operating room. NMBAs are used to facilitate tracheal intubation and
provide optimal surgical conditions. The use of NMBAs requires the administration of a reversal
agent such as sugammadex or neostigmine. However, a risk of using NMBAs is incomplete
recovery from the reversal of the medication, also known as residual neuromuscular blockade.
Residual neuromuscular blockade can be benign or lead to catastrophic events, most known as
postoperative pulmonary complications (PPCs). A population most at risk for PPCs is patients
with obstructive sleep apnea (OSA). Effective use of neuromuscular blockade reversal
medications may reduce adverse outcomes for patients with OSA.
Background
There are two types of neuromuscular blockers—depolarizing and non-depolarizing.
Depolarizing neuromuscular blocking agents, such as succinylcholine, mechanism of action is
continuous depolarization of the postsynaptic neuromuscular junction (NMJ) resulting in shortterm muscle paralysis. Depolarizing neuromuscular blockers do not require the use of a reversal
agent due to the rapid breakdown of the drug by pseudocholinesterase. Non-depolarizers work
by competitively inhibiting post-junctional nicotinic Acetylcholine (ACh) receptors in the NMJ.
The binding of non-depolarizing NMBAs prevents the depolarization of the NMJ resulting in
flaccid paralysis (Cook & Simons, 2021).
Non-depolarizers are categorized based on their chemical structures into amino-steroidal
and benzylisoquinoliniums. Benzylisoquinoliniums such as mivacurium, atracurium, and
cisatracurium, are eliminated via organ independent degradation. Due to the differences in
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chemical structure, benzylisoquinoliniums’ effects can only be reversed with the administration
of neostigmine. The two amino-steroidal agents—rocuronium and vecuronium, are dependent
on organs for metabolism and excretion of the medication. Rocuronium’s onset is 1-2 minutes,
the peak is 90 seconds, and the duration is 20-35 minutes. The onset and peak of vecuronium are
3-5 minutes and the duration of action is 20-35 minutes (Vargo Anesthesia Inc, 2021). The
unique chemical structure of rocuronium and vecuronium allows for reversal with either
neostigmine or sugammadex.
Rocuronium and vecuronium bind competitively to the ACh receptors and can be
overcome by the administration of acetylcholinesterase inhibitors such as neostigmine.
Neostigmine works by inhibiting the breakdown of acetylcholine thus increasing the
concentration of ACh at the NMJ. ACh then outnumbers the rocuronium or vecuronium and
allows for depolarization to occur. The onset of neostigmine is 1-5 minutes, peaking at 7-14
minutes and lasting 30-60 minutes (Vargo Anesthesia Inc, 2021). The concentration of ACh not
only increases at the NMJ but systemically. The increased concentration of ACh systemically
directly leads to a plethora of side effects such as bradycardia, bronchoconstriction, salivation,
and increased gastric motility. Neostigmine has also been associated with an increase in
postoperative nausea and vomiting (PONV). The concomitant administration of glycopyrrolate,
an anti-cholinergic, is needed to reduce these side effects. Glycopyrrolate antagonizes
acetylcholine at muscarinic receptor sites, thus offsetting systemic detrimental side effects of
neostigmine. Glycopyrrolate does not affect acetylcholine at nicotinic receptor sites, such as in
the NMJ. Another reversal agent for amino-steroidal NMBAs is sugammadex. Sugammadex
works by irreversibly binding to the amino-steroidal NMBAs, rocuronium and vecuronium, and
is eliminated in the urine. Sugammadex has potential side effects of anaphylaxis, bradycardia,
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PONV, and reduces the effectiveness of hormonal contraceptives. Sugammadex onset is 3
minutes, and the half-life is 2 hours (FDA, 2015).
Significance Related to Nurse Anesthesia
A risk of using NMBAs is residual neuromuscular blockade leading to PPCs, and patients
with OSA are at an increased risk for these events. PPCs include any unanticipated hypoxemia,
hypoventilation, or upper airway obstruction requiring an active and specific intervention.
Obstructive sleep apnea (OSA) is identified in the literature as a condition that is associated with
pulmonary complications in the immediate postoperative period (Li et al., 2021). OSA is
defined as a “breathing disorder, prevalent in the obese population, distinguished by periodic,
partial, or complete obstruction of the upper airway during sleep” (Nagelhout & Elisha, 2018).
Patients at risk for OSA are often identified with screening tools such as the STOP-Bang
Questionnaire. The questionnaire includes an assessment of snoring, tiredness, observed apnea,
high blood pressure, body mass index (BMI), age, neck circumference, and gender.
The risk of residual neuromuscular blockade associated with rocuronium or vecuronium
administration and the possibility of pulmonary complications in patients with OSA necessitates
total and prompt reversal of neuromuscular blockade. Before Food and Drug Administrations
(FDA) approval of sugammadex in 2015, neostigmine was the only option for the reversal of
rocuronium and vecuronium. Sugammadex now offers an alternative to rocuronium and
vecuronium reversal. The upfront cost associated with sugammadex is often cited as the reason
for the uninhibited use of the medication (Carron et al., 2017).
Raval et al. (2020) evaluated 20 randomized control trials (RCTs) and found at two
minutes after sugammadex administration residual neuromuscular blockade was 19.8% and
declined to 2.8% at six minutes versus neostigmine of 100% and 82% respectively for a
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moderate block. The same study also found that residual neuromuscular blockade was reduced
to 1% fifteen minutes after administration of sugammadex for a deep block while neostigmine
remained at or above 95% for 60 minutes after administration. Kheterpal et al. (2020) found a
30% reduction in pulmonary complications including a 47% reduced risk of pneumonia and a
55% reduced risk of respiratory failure associated with sugammadex when compared to
neostigmine.
It is important to consider the clinical outcomes associated with each reversal medication
while considering patient safety and the overall cost-effectiveness for the hospital system. The
average cost associated with a PPC, the amount of time in the post anesthesia recovery care unit
(PACU), and the operating room (OR) turnover time should be considered in addition to the
upfront cost of each medication. The purpose of the project is to explore the differences in
clinical outcomes and cost-effectiveness of neostigmine and sugammadex in OSA patients
undergoing surgery.
PICO Question
Utilizing our previously described problem, a PICO formatted question was derived to
guide a literature search. The PICO format will be used to provide strategic key search terms to
obtain the best evidence in this project. The four components of a PICO question include
“population of interest [P], intervention of interest [I], comparison of interest [C], and outcome
of interest [O]” (Mazurek-Melnyk & Fineout-Overholt, 2019). In (P) surgical patients who are
diagnosed with or identified as high risk for OSA, (I) how does the use of sugammadex for
reversal of amino-steroidal non-depolarizing blockers (C) compared to neostigmine (O) affect
postoperative patient outcomes and cost-effectiveness related to postoperative pulmonary
complications and time in PACU?
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Projective Objectives
The purpose of this project is the development of evidence-based practice
recommendations with a plan for implementation and evaluation of these recommendations.
From this purpose, the objectives for this project are listed below.
1) Synthesize evidence from the literature search for use of sugammadex or neostigmine
for reversal of NMBAs.
2) Develop evidence-based practice recommendations for the reversal of rocuronium
and vecuronium in patients at risk for OSA.
3) Develop a comprehensive plan to implement, monitor, and adjust these
recommendations which include a cost-benefit analysis and evaluation of patient
outcomes for patients with OSA.
Literature Search
Project Question and Search Terms
To investigate the aforementioned clinical outcomes and cost-effectiveness, a literature
review was conducted utilizing the above PICO question. The international electronic databases
that were used were Cochrane Database of Systematic Reviews (CDSR), Medline, and the
Otterbein University library database. Key search terms were broken down by each aspect of the
PICO(T) question. For the patient population (P), the search terms: surgical patients and
obstructive sleep apnea were utilized. To explore the intervention (I), search terms:
sugammadex, neostigmine, neuromuscular blocking agents, rocuronium, vecuronium, and
glycopyrrolate were used. The search terms focused on the outcomes (O) included: postoperative
patient outcomes, cost, cost-effectiveness, postoperative pulmonary complications, reintubation,
aspiration, residual neuromuscular blockade, time, and time in PACU. The main Boolean
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operator used was “and” to connect these keywords. All search results were narrowed to peerreviewed literature, conducted in or translated to English, and published within the last decade.
Organization and summarization of the literature articles were completed utilizing a level of
evidence synthesis table (Appendix A).
Postoperative Pulmonary Complications and Obstructive Sleep Apnea
To better understand how neuromuscular blocking agents and their residual effects can be
detrimental to patients with obstructive sleep apnea (OSA), obstructive sleep apnea must be
defined and related to PPCs according to the literature. According to Nagelhout & Elisha (2018),
OSA is the result of relaxation of pharyngeal muscle that subsequently causes airway obstruction
during sleep. The prevalence of OSA has continued to rise within the United States due to the
obesity pandemic (Chung & Mokhlesi, 2014). It is estimated that up to 24% of males and 9% of
females have OSA (Nagelhout & Elisha, 2018). One of the primary risk factors for developing
OSA is obesity (Nagelhout & Elisha, 2018).
The incidence of encountering surgical patients with OSA is continuing to increase as the
obesity epidemic and the overall number of surgeries per year increases (Chung & Mokhlesi,
2014). This is of the utmost importance for anesthesia providers due to the mechanism of action
of many of the drugs administered peri-operatively, including neuromuscular blocking agents,
narcotics, and sedatives (Chung & Mokhlesi, 2014). Neuromuscular blocking drugs (NMBDs)
act directly on pharyngeal musculature, causing varying degrees of weakness that results in
mechanical obstruction of the airway and impairs effective ventilation (Miskovic & Lumb,
2017). The residual effects of NMBDs leftover from reversal with sugammadex or neostigmine
can result in postoperative residual blockade (PORB) and concurrent pulmonary complications
(Miskovic & Lumb, 2017). These effects are even more prevalent in surgical patients with OSA
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and can be seen even if clinically adequate recovery appears achieved (Miskovic & Lumb,
2017).
Surgical patients with OSA who receive a NMBD and subsequent reversal with
sugammadex or neostigmine are at higher risk of developing PPCs compared to non-OSA
patients (Kaw et al., 2012). Kaw et al. (2012) conducted a meta-analysis of thirteen studies
involving nearly 4,000 patients that concluded that surgical patients with OSA were at a higher
risk of “postoperative desaturation, respiratory failure, postoperative cardiac events, and ICU
transfers.” The systematic review by Hafeez et al. (2018) concluded that OSA was an
independent risk factor for developing a PPC and the occurrence of a PPC increased overall
mortality. A multi-center study by Fernandez-Bustamante et al. (2017) concluded that even mild
PPCs, such as supplemental oxygen, were strongly associated with “increased early
postoperative mortality, ICU admission, and length of stay (ICU and hospital).” The authors go
on to state that even mild PPCs can hinder patient outcomes and subsequently increase the cost
of care and thus attention and intervention should be implemented to improve clinical and
financial outcomes (Fernandez-Bustamante et al., 2017).
Not only are PPCs associated with an increase in mortality, but also an increased cost as
additional interventions may be needed and length of stay extended (Miskovic & Lumb, 2017).
Miskovic & Lumb (2017) found that pneumonia and respiratory failure because of PPCs
contributed to a roughly 45% increase in overall cost. To highlight the magnitude of PPCs and
associated cost, Fleisher & Linde-Zwirble (2014) reviewed 45,969 records of discharged
gastrointestinal surgical patients and found that PPCs were present in 22% of cases and averaged
an additional cost of $25,498.
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Screening for OSA
As discussed above, OSA places a patient at higher risk for respiratory complications
following a surgical procedure. However, the majority of surgical patients with OSA remain
undiagnosed at the time of surgery (Nagappa et al., 2015). It is important to identify these
patients during the pre-operative period so that they can be appropriately monitored and
managed throughout the perioperative experience. While the gold standard for diagnosis of OSA
is an overnight polysomnogram, this is not an option at the time a patient is presenting for a
procedure. The STOP-Bang questionnaire is an assessment tool that can be completed in minutes
and utilized to identify patients who are at risk for sleep apnea. The tool includes four subjective
questions about snoring, tiredness, observed apnea, and high blood pressure. The other four
items scored include demographics such as BMI greater than 35 kg/m2, age over 50, neck
circumference greater than 40 cm, and male gender. Each item is answered yes or no and a score
less than three is a low risk while greater than or equal to three is high risk (Nagelhout & Elisha,
2018).
Nagappa et al. (2015) explored the validity of the STOP-Bang screening tool through a
systematic review and meta-analysis. The high-level review and analysis included seventeen
studies including 9,206 patients. Of the seventeen studies found, all of the studies used a
polysomnogram test for confirmation of obstructive sleep apnea initially identified by a STOPBang score. Overall, the study found the probability of moderate to severe obstructive sleep
apnea increased as the STOP-Bang score increased (Nagappa et al., 2015).
Clinical Outcomes of Sugammadex versus Neostigmine as Reversal Agents
PPCs due to residual neuromuscular blockade are always a risk when NMBDs are
administered. The NMBDs focused on in this project are the amino-steroidal neuromuscular
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blocking drugs, rocuronium and vecuronium. After administration of rocuronium or vecuronium,
sugammadex or neostigmine with glycopyrrolate must be given to reverse the paralytic effects
and decrease the likelihood of residual neuromuscular blockade that can lead to PPCs
(Brueckman et al., 2015). As stated above, Miskovic & Lumb (2017) found that even if
appropriate clinical indicators demonstrate adequate reversal, residual neuromuscular blockade
may still exist postoperatively leading to PPCs. Furthermore, surgical patients with OSA are
even more sensitive to the residual effects of rocuronium and vecuronium, potentially leading to
mild or catastrophic PPCs (Li et al., 2021). As evidenced above, PPCs not only lead to an
increase in mortality but also the overall cost of healthcare (Fernandez-Bustamante, 2018). Thus,
the literature search aims to elucidate the most up-to-date evidence-based practice regarding
sugammadex and neostigmine and associated clinical outcomes and cost-effectiveness.
One of the most prominent studies involving sugammadex and neostigmine is the
STRONGER trial by Kheterpal et al. (2020). The current mainstay practice in many facilities and
by anesthesia providers in the United States is the administration of neostigmine over
sugammadex due to familiarity with neostigmine and lower cost. The STRONGER study
challenges the inhibited use of sugammadex in comparison with neostigmine due to familiarity
and cost-effectiveness. The extensive, multicenter observational matched-cohort study consisted
of 12 hospitals involving 45,712 patients receiving either sugammadex or neostigmine. The
primary composite recorded was PPCs feasibly related to neuromuscular blocking agents
rocuronium or vecuronium. PPCs in this study were defined as pneumonia, respiratory failure, or
other major pulmonary complications (Kheterpal et al., 2020). Perioperative variables were noted
to be extremely balanced throughout both the sugammadex group and neostigmine group
concerning the patient, procedure, and intraoperative care factors. The trial results demonstrated
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a 30-50% decreased risk of pneumonia and respiratory failure with the use of sugammadex
compared to neostigmine (Kheterpal et al., 2020). In terms of cost-effectiveness, Kheterpal et al.
(2020) estimate that the average cost of a major pulmonary complication as described in this
study equates to nearly $100,000.
Our most relevant and highest level of evidence study came from a systematic review
conducted in 2018 investigating the postoperative pulmonary complications associated with
neuromuscular blocking drugs or reversal agents in patients with obstructive sleep apnea (Hafeez
et al., 2018). “Postoperative complications with neuromuscular blocking drugs and/or reversal
agents in obstructive sleep apnea patients” initially included 4,123 studies, but only five studies
were permitted due to stringent inclusion criteria. Of these five studies, totaling 1,126 patients,
two studies were randomized controlled trials (RCT) and three were observational studies.
Hafeez et al. (2018) recommend that higher-quality studies are needed to clarify the effects of
sugammadex and neostigmine on postoperative pulmonary complications in patients with OSA.
The STRONGER trial and this systematic review involving multiple studies agree that
sugammadex appears to be superior to neostigmine in preventing PPCs. Hafeez et al. (2018)
suggested that higher-quality studies needed to be performed, during which the STRONGER
trial was still being completed.
Unal et al. (2020) published a study in the Turkish Journal of Anaesthesiology &
Reanimation that focused on outcomes such as train of four (a tool used to monitor
neuromuscular blockade depth), operating room time, post-anesthesia care unit (PACU) time,
postoperative respiratory complications, costs related to neuromuscular block reversal and
follow-up and treatment complications. The study involved patients undergoing surgery with a
diagnosis of OSA. The results of the study demonstrated a decreased incidence of PPCs in the
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sugammadex group along with a higher reversal cost compared to the neostigmine group (Unal
et al., 2020). Although the reversal cost was higher in the sugammadex group, the overall followup and treatment costs for neostigmine vastly outweighed the cost of sugammadex (Unal et al.,
2020). Although the results seem promising for sugammadex, major limitations exist within this
study such as: only rocuronium was used, a small sample size of 74 patients, and the patient’s
American Society of Anesthesiologists (ASA) physical status was I or II which does not seem
accurate if the patients have a history of OSA already (Unal et al., 2020).
A meta-analysis by Carron et al. (2017) explored patient discharge readiness between
sugammadex and neostigmine after neuromuscular blockade reversal. Carron et al. (2017)
highlighted the fact that sugammadex is known to be faster and more effective at reversing
deeper blockades than neostigmine. The authors argued that prior studies suggesting otherwise
either based sugammadex dosing on qualitative monitoring instead of the recommended
quantitative monitoring leading to the administration of an inadequate dose. Carron et al. (2017)
state that these prior studies reflect “inappropriate use rather than failure of the drug.” Thus, this
study performed a meta-analysis involving 518 patients from six studies where the time from
operating room (OR) to PACU was tracked, along with time from PACU to the surgical ward.
The results of this study concluded that sugammadex was superior at discharging patients from
the OR to the PACU but did not show superiority for discharge from PACU to the surgical ward
(Carron et al., 2017). Although this meta-analysis did not reflect superior patient clinical
outcomes such as reduced PPCs, it did reflect a faster discharge from the OR which would lead
to faster turn-over time and increased cost-effectiveness. Carron et al. (2016) is a retrospective
analysis by the same authors who conducted the meta-analysis in 2017. In this retrospective
analysis, Carron et al. (2016) investigated clinical outcomes and cost-effectiveness of
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sugammadex at their own University Hospital of Padova in Italy. The most commonly occurring
PPC was difficulty weaning from the ventilator, hypoxemia, respiratory distress, and respiratory
failure (Carron et al., 2016). Sugammadex demonstrated a reduced number of PPCs in
comparison to neostigmine. In addition to a reduced number of PPCs, the sugammadex group
had 1 intensive care unit (ICU) admission compared to the neostigmine group which had 10
(Carron et al., 2016). The sugammadex group had an average recovery room stay of 56 minutes
while the neostigmine group had an average recovery room stay of 103 minutes. Overall, Carron
et al. (2016) concluded that neuromuscular blockade that was reversed with sugammadex
demonstrated a reduced risk of residual neuromuscular blockade and subsequence PPCs.
Cost Associated with Sugammadex versus Neostigmine as Reversal Agents
While patient safety and the clinical outcomes associated with each reversal agent take
the highest priority when recommendations are created for the use of reversal agents, hospitals
must also consider the costs connected with each drug and the subsequent costs related to
complications or lack thereof. Train of four (TOF) monitoring should be utilized to assess the
degree of neuromuscular blockade throughout the surgery and immediately before the
administration of a reversal agent (Nagelhout & Elisha, 2018). A peripheral nerve stimulator, or
train of four, delivers four electrical impulses to the patient and the user counts the number of
twitches elicited. The dose of reversal medication is then calculated based on the number of
twitches and the patient’s body weight (Flood et al., 2014).
The dose of neostigmine is 0.02-0.08 milligrams (mg)/kilogram (kg) dependent on the
number of twitches elicited. For two of four twitches with fade, 0.07 mg/kg should be
administered. For four of four twitches with fade 0.04 mg/kg should be administered (Vargo
Anesthesia Inc, 2021). As discussed above, glycopyrrolate must be administered concomitantly
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with neostigmine to offset the side effects. For every 1 mg of neostigmine given, 0.2 mg of
glycopyrrolate should be administered. The average wholesale price of neostigmine is $22.03
for a 10 mg/10 milliliter (mL) multi-dose vial and $20.81 for a 5 mg/10 mL multi-dose vial. The
average wholesale price for glycopyrrolate is $8.40 for a 0.2 mg/1 mL single-dose vial and
$16.68 for a 0.4 mg/2 mL single-dose vial (Deyhim et al., 2020).
Sugammadex dosing is also based on the number of elicited twitches and the patient’s
weight. If two of four twitches are elicited, 2mg/kg of sugammadex should be administered.
Sugammadex can be used if no twitches are elicited at a dose of 4mg/kg and in an emergency
after an intubating dose of rocuronium has been administered at 16 mg/kg. Sugammadex does
not require any other drug to be administered with it (Vargo Anesthesia Inc, 2021). The average
wholesale price of sugammadex is $219.24 for a single-dose 500 mg/5mL vial and $119.69 for a
single-dose 200 mg/2 mL vial (Deyhim et al., 2020).
Along with the upfront price of reversal agents, the costs associated with time for reversal
and adverse events associated with the medication must also be evaluated. Hurford et al. (2020)
estimated the direct cost for OR time is $32.49 per minute, postoperative mechanical ventilation
at $2,631.85 per day, and the cost associated with PONV to be $98.62. Ultimately, the net cost
for sugammadex was found to be $225 lower than the net costs associated with reversal with
neostigmine and glycopyrrolate. The largest cost savings for sugammadex was attributed to a
reduction in non-operative OR time (Hurford et al., 2020).
To summarize, this literature search, review, and synthesis offered promising evidencebased support of the use of sugammadex over neostigmine to improve clinical outcomes and
cost-effectiveness in surgical patients with OSA. An overwhelming majority of studies
highlighted the superiority of sugammadex over neostigmine in terms of residual neuromuscular
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blockade and subsequent PPCs. Regarding surgical patients with OSA, it is safe to say that the
literature unanimously elucidates patients with OSA are considered an “at-risk” population for
PPCs after administration of a NMBD (Hafeez et al., 2018). Not only does sugammadex provide
clinical outcome benefits by reducing incidences of PPCs, but the drug also demonstrates an
ability to be cost-effective simultaneously (Carron et al., 2016).
Model Used for Project Framework
The theoretical framework utilized for this project was the John Hopkins Nursing
Evidence-Based Practice model (JHNEBP) (Dang & Dearholt, 2022) (Appendix B). Listed in
Appendix B is the “Copyright Permission Form” completed through John Hopkins Medicine
Institution that granted access to use the evidence-based practice model and tools. This model
was chosen due to its ability to solve clinical decision-making problems with evidence-based
practice (Dang & Dearholt, 2022). Additionally, by utilizing the signature three-step process
called PET, users can efficiently incorporate the most up-to-date practices into patient care
(Dang & Dearholt, 2022). The three-step process includes: asking a practice question (P),
synthesizing the evidence (E), and translating the evidence into best practice (T) (Dang &
Dearholt, 2022).
The first phase of the model included identifying the practice question utilizing a six-step
process (Dang & Dearholt, 2022). First, a team was developed that consisted of two DNP
students, the project advisor, pharmacy, and the quality control department within the
organization. Second, the presence of inconsistency within the current clinical practice was
identified to define the problem. Sugammadex and neostigmine are both used to reverse the
effects of neuromuscular blocking agents (Nagelhout & Elisha, 2018). Each drug has a differing
mechanism of action and subsequent side effects associated with its use. No clear policies or
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guidelines are in place to support the use of one drug over the other. Additionally, certain at-risk
populations can be predisposed to the side effects of neuromuscular blockade reversal, such as
patients with obstructive sleep apnea (Miskovic & Lumb, 2017). Third, the following evidencebased practice (EBP) question was constructed: How do the clinical outcomes and costeffectiveness of sugammadex compare to neostigmine with glycopyrrolate in surgical patients
with obstructive sleep apnea? Fourth, the stakeholders associated with this project were
identified and included patients, certified registered nurse anesthetists, (CRNAs),
anesthesiologists, pharmacy, quality control team, hospital administration, and the organization.
Fifth, the two partnered DNP students determined leadership for the project and met weekly to
discuss project goals, visions, knowledge, and overall direction. Last, quarterly meetings were
scheduled and held between the DNP students and project advisor to facilitate progressive
project completion and success.
The second phase of the model will include synthesizing the evidence and consists of a
five-step process (Dang & Dearholt, 2022). First, internal evidence will be collected through the
quality control department that monitors for pre-determined quality goals throughout different
departments. Specifically, data on postoperative pulmonary complications will be gathered.
External evidence will be collected by utilizing a comprehensive literature search that will be
synthesized. Second, Appendix A contains the level of evidence synthesis and outcomes table.
Steps 9 and 10 (third and fourth in the 5 step process for this phase) were demonstrated by the
evidence showing a strong correlation between postoperative pulmonary complications (PPCs)
and patients with obstructive sleep apnea. Additionally, the evidence overwhelmingly supported
the use of sugammadex over neostigmine with glycopyrrolate when reversing neuromuscular
blocking agents in terms of clinical outcomes and cost-effectiveness. For completeness, Hafeez

OUTCOMES OF NMBD REVERSAL IN PATIENTS WITH OSA

18

et al. (2017) is a meta-analysis that concluded that sugammadex did demonstrate some evidence
of being superior but recommended additional high-quality studies. Since then, Kheterpal et al.
(2020) conducted an extensive trial that demonstrated significantly lower rates of PPCs
associated with the use of sugammadex. Lastly, recommendations were developed for this
practice change (Appendix D).
Phase three involves translating the evidence into project implementation (Dang &
Dearholt, 2022). The most feasible project implementation option is to conduct an organizational
assessment that monitors the appropriate outcomes and data. First, organizational access to
quality control data will need to be obtained. Secondly, an organizational assessment will be
conducted that investigates the project’s focus involving surgical patients with OSA, the use of
sugammadex or neostigmine, and the associated rate of PPCs. Dissemination of the results of the
organizational assessment will be provided to the appropriate stakeholders and departments
along with the external evidence gathered throughout multiple databases.
Recommendations
Based on the information gathered from the literature search presented above, the use of
sugammadex for reversal of rocuronium or vecuronium in patients with sleep apnea decreased
the occurrence of PPCs. Therefore, the following recommendations for neuromuscular reversal
should be considered: A formatted document can be found as Appendix D.
1. Every surgical patient should be screened for sleep apnea with the STOP-Bang
screening tool during the pre-operative period.
•

Patients with obstructive sleep apnea often remain undiagnosed at the time of
arrival for their procedure. It is important to identify these patients early in the
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perioperative experience so that they can be treated and monitored appropriately.
Therefore, each patient screened for sleep apnea preoperatively.
2. A patient identified as at risk for obstructive sleep apnea, as identified by a STOPBang score greater than 3, or with a previous diagnosis of sleep apnea should be reversed with
sugammadex.
•

A literature review revealed a higher incidence of pulmonary complications for
patients with obstructive sleep apnea. The literature review also revealed fewer
postoperative complications when these patients were reversed with sugammadex.
Therefore, patients diagnosed with or identified as at risk for obstructive sleep
apnea should be reversed with sugammadex to decrease the incidence of
postoperative complications. The dosing of sugammadex should follow the
manufacturer’s guidelines.

3. If patient scores less than 3 on STOP Bang scale, choice of reversal agent should be
deferred to clinician judgement with consideration of other patient comorbidities.
•

Although sugammadex is recognized clinically as the superior reversal agent in
the literature, its use should not go uninhibited. As stated above, sugammadex is
recommended as the reversal agent of choice in patients with a diagnosis of OSA
or a STOP-BANG score of 3 or greater to reduce the likelihood of PPCs in this
susceptible population. In populations who are not at an increased risk of PPCs,
and received either rocuronium or vecuronium, neostigmine should still be
considered if appropriate (Cammu, 2018). Additionally, patient comorbidities
should be evaluated and the risk and benefit of administering sugammadex or
neostigmine should be performed on a case-by-case basis (Cammu, 2018).
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Comprehensive Plan for Enactment of Recommendations
In collaboration with the project team leader and team members, it was determined the
project does not need IRB approval as the project does not involve human subjects. The IRB
exemption can be located in Appendix C. This project will include retrospective quantitative data
that will be gathered by the DNP students after acquiring the appropriate access to the data from
the organization. After obtaining approval, the retrospective quantitative data will be acquired
and organized to reflect the presence of a clinical problem. For the purpose of this project, an
unidentified Midwest level 1 trauma center will be the organization of focus.
The project team members have constructed a plan for future implementation within an
organization. To implement this project in the future, the project team will first perform a
detailed chart audit involving a retrospective analysis of all surgical patients with a diagnosis of
OSA or a STOP-BANG score of 3 or greater who also received rocuronium or vecuronium. The
specific data points that will need to be collected are: which reversal agent was given and the
amount, time from reversal agent administration to OR exit, time in PACU, reintubations in
PACU/OR, aspiration pneumonia diagnosis within 48 hours of surgery, oxygen desaturation
below 90% after extubation until PACU discharge, and overall length of stay (LOS) if a PPC
occurred. Second, a thorough and complete literature search, such as the one completed above,
will need to be performed so that the appropriate recommendations can be construed. The
findings from the initial chart audit should be organized and composed into an easy-to-read
graphic. Next, analyze and synthesize the literature search and summarize the cost-benefit
analysis so the information can be displayed to the appropriate key stakeholders and committees
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within the facility. Once approved, begin educating the appropriate departments on the
recommendations during staff meetings, through lamented educational sheets and email.
Cost-Benefit Analysis
A cost-benefit analysis can be used to evaluate the financial implications of a decision.
As previously mentioned, the up-front cost associated with purchasing sugammadex is often
cited as the reason for reserving the use of the medication for emergencies. A cost-benefit
analysis of neostigmine and sugammadex should be performed to determine the most costeffective method for reversing neuromuscular blockade in patients with OSA.
The information from the chart audit should be condensed and used to complete the costbenefit analysis. The average time from reversal administration to OR exit, time in PACU,
number of adverse events, and the length of stay associated with an adverse event should all be
taken into consideration for each medication. Using the information presented in the literature
search section above, the up-front cost of the medications should be compared with the cost of
the average time from reversal administration to OR exit, average PACU time, associated
adverse events, and additional length of stay. The drug found to be associated with the overall
lowest cost, after comparing the upfront cost to associated costs, should be considered the most
cost-effective.
It is also important to consider billing and reimbursement from insurance companies
and/or Medicare/Medicaid. At the hospital of interest, the patient is charged for medications that
are charted. Some hospitals may have a universal charge for all anesthesia medications. It is
important to know how the medications are billed for when completing the cost-benefit analysis.
It is also important to consider legal costs that may be associated with adverse events related to
neuromuscular blockade reversal administration. The legal costs may not be captured in the 1-
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year audits, but they should be captured in the 3 and 5-year audits. While litigation costs may be
delayed, they can be significant and are necessary to include for a complete analysis. Once
completed, the findings from the cost-benefit analysis should be included in the presentation to
key stakeholders.
Timeline
The timeline for the project leaders to implement the developed recommendations at the
specified facility will occur over a period of 1 year. Initially, education will need to be presented
to the following key stakeholders: anesthesiologists, certified registered nurse anesthetists, postanesthesia care unit nurses and unit managers, operating room pharmacists, and the appropriate
quality department at the facility. The project leaders will need to conduct in-person meetings
with each department so that the recommendations can be enacted appropriately. The first week
of rolling out the project will consist of in-person meetings with the anesthesia department,
PACU, and pharmacy. During that same week, lamented educational sheets will be dispersed in
every operating room and procedural area where general anesthesia occurs. Pharmacy will need
to coordinate efforts to ensure each Pyxis is stocked with sugammadex during this first week of
the rollout. The PACU nurse manager and nurses will be informed of what specific clinical data
to monitor for and document appropriately. The quality department will monitor for sentinel
events and adherence to the recommendations so that an accurate clinical and cost-benefit
analysis can be completed.
After the initial rollout of the recommendations, the project leaders will then focus their
efforts on maintaining compliance with the recommendations and reminders. After 1 year has
passed, the project leaders will conduct a second retrospective chart audit from the second week
of project rollout up to the 1-year mark. The aforementioned data points will be collected again
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along with compliance with the recommendations gathered by the quality department. The data
points will be organized and compared to the previous data points collected in the first chart
audit to display the project’s results thus far.
If the project recommendations fail to display a reduction in PPCs or cost after 1 year, the
recommendations will be discontinued, and the provider’s preference will be encouraged.
Further monitoring will be conducted by the project leaders at 3- and 5-year time intervals from
the start of the project to monitor for any legal ramifications associated with adverse events
related to PPCs.
Budget
The budget for the project should include expected incurred expenses for the rollout and
monitoring of the recommendations. The main expense will be acquiring the appropriate amount
of sugammadex vials so that every surgical patient with OSA who receives a non-depolarizing
neuromuscular blocking agent can be reversed with sugammadex. The average wholesale price
of sugammadex is $219.24 for a single-dose 500 mg/5mL vial and $119.69 for a single-dose 200
mg/2 mL vial (Deyhim et al., 2020). The occurrence of OSA is hard to pinpoint but can be
estimated to be around 20% in the general population (Senaratna et al., 2016). Thus, if the data is
extrapolated to the number of surgeries performed daily at the unidentified Midwest level 1
trauma center, we can conclude that a safe number of sugammadex vials to have available daily
is 50. The 50 vials will be divided into 40 vials of 200mg and 10 vials of 500mg. Thus, the total
cost of the daily sugammadex budget is $6,980. This sum will not be spent daily due to the usage
of sugammadex being tracked thereby ensuring that a surplus is not purchased.
A meeting with the pharmacy may be necessary to discuss the anticipated extra need for
sugammadex and the stocking of sugammadex in the medication cart. If extra time is required
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outside of a normal workday, pay for the pharmacist should also be factored into the budget. The
medication cart may need to be rearranged to accommodate the extra sugammadex vials. While
it is likely the sugammadex vials can be stocked in place of the neostigmine vials, larger
medication carts may need to be factored into the budget if rearranging the medications is not
possible. The recommendations will be presented at required weekly staff meetings and there are
not any expected additional monetary expenses expected related to the dissemination of the
recommendations.
Additional expenses include paper materials required to present evidence-based literature
findings. A total of $50 will be allotted for material expenses. Other expenses were considered
such as time conducting a literature search, and synthesis, meetings with stakeholders, and time
spent developing the project paper and presentation. These time expenses will be endured by the
project leaders and will not contribute to the overall monetary project budget.
Comprehensive Plan for Monitoring and Measuring Recommendations
The primary outcomes that will be monitored are time from neuromuscular blockade
reversal administration to the time of operating room exit, total time in PACU, and complications
associated with PORB which include re-intubation, oxygen desaturation, and aspiration
pneumonia. Two secondary outcomes that would be measured if a complication from PORB
occurs are the length of stay and instances of litigation related to sentinel events. Re-intubation
will consist of any intubation that occurs after extubation and before discharge of PACU. The
occurrence of pneumonia will be counted if it occurs within 48 hours of extubation. Oxygen
desaturation will be defined as any accurately measured SpO2 saturation of less than 90% that
occurs before discharge from PACU. To assess for compliance with recommendations, the audit
will also collect which reversal agent was used and the dose administered. These data points can
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be collected by the QA/QI department and presented to the project leaders at the appropriate time
intervals.
The time intervals that would be used for this project are 1, 3, and 5-years. The one-year
interval would allow a substantial amount of primary outcome data to accumulate and compare
to the retrospective data already collected. The three- and five-year intervals would allow an
ample amount of time for legal action to have taken place regarding sentinel events potentially
related to PORB. This data is pertinent because it will highlight the difference in costeffectiveness between neostigmine and sugammadex related to tremendous litigation fees. At
each time interval, the proposed data points will be collected, analyzed, and compared to the
retrospective data collected previously which will allow a thorough comparison of neostigmine
and sugammadex.
The data would be analyzed by comparing the most recent data to the findings from the
initial chart audit. If the recommendations are successful, a reduction should be seen in the OR
time, PACU times, and the number of adverse events related to PORB. The collected data should
also be analyzed for compliance with the recommendations. A lack of compliance with the
recommendations may skew the data to look as if the recommendations have failed. Therefore,
the data must be analyzed for compliance before comparing the data to the initial chart audit
findings.
Comprehensive Plan for Revisions
Before comparing the initial chart audit and the most recent, recommendation compliance
will be investigated to ensure the data will not be skewed. Afterward, if the proposed
recommendations are not found to be effective, then the appropriate revisions will be made. If
recommendation compliance is not satisfactory, additional education would be provided as well
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as following up with providers who are not adhering to the recommendations. If no difference in
cost-effectiveness or clinical outcomes is elicited during the conclusion of the one-year interval,
the proposed recommendations would be redacted, and provider preference would be
encouraged. The project leaders will continue monitoring the 3- and 5- year intervals for possible
litigation related to PORB and report any findings.
Dissemination
Utilizing the extensive literature search, the project leaders will compose a poster
presentation highlighting the synthesized literature along with the plan for enactment,
monitoring, and adjustments. The dissemination will involve the project team members, key
stakeholders, faculty staff, and scholarly peers. Relevant background information will be
presented by the project leaders along with why this topic is of importance. Subsequently, a
concise but thorough literature review will be presented highlighting the most evidence-based
practice recommendations. Lastly, a plan that includes enactment, monitoring, and adjustment
will be displayed that details how the project can be rolled out at a facility.
Conclusion
The literature search confirmed patients with OSA are more susceptible to PPCs related
to residual neuromuscular blockade. Currently, evidence-based recommendations are minimal, if
not absent, to guide NMBA reversal in patients with OSA. A synthesis of the literature
concluded that sugammadex is associated with a reduced incidence of PPCs in patients with
OSA. The significant cost of a PPC can be avoided by using sugammadex in this patient
population. After a thorough literature search, the project team concluded all surgical patients
should be screened for OSA prior to their procedure. Patients previously diagnosed with OSA or
demonstrated to be at risk for OSA by a STOP-Bang score greater than 3 should be reversed with
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sugammadex if they received rocuronium or vecuronium. However, more research is needed
before recommendations can be made for the uninhibited use of sugammadex in all populations.
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Appendix A

Levels of Evidence Synthesis Table
Citation

Conceptual
Framework

(Author,
Year, Title,
etc…)

(Theoretical
basis for study)

Design/
Method

Sample/Setting

(Number,
Characteristics,
Exclusions, Criteria,
Attrition, etc…)

Major Variables;
definitions

Outcome
Measurement

Data Analysis

(Independent variables;
Dependent variables)

(What scales used –
reliability information –
alphas)

(What stats used?)

Findings

(Statistical findings or
qualitative findings)

Level
of
Eviden
ce
Level
=

Quality
of Evidence
Strength
Limits
Risks
Feasibility

Article 1: Postoperative complications with neuromuscular blocking drugs and/or reversal agents in obstructive sleep apnea patients: A systematic review

See below

Not evident

Systematic
Review

Out of 4123 studies,
five studies (2 RCTs
and 3 observational
studies) were
deemed eligible.

Patients who were given
NMBD and/or NMBD
reversal agents
intraoperatively; risk of
postoperative
complications from the
use of NMBD than nonOSA patients

Risk of developing
postoperative
pulmonary
complications (PPCs)
like hypoxemia,
residual
neuromuscular
blockade, or
respiratory failure
compared to non-OSA
patients

Incidence of PORC,
adverse events with
sugammadex, and
neostigmine

OSA patients who
received
intraoperative NMBD
may be at higher risk
for postoperative
residual
neuromuscular
blockade, hypoxemia,
and respiratory
failure. The use of
sugammadex was
associated with less
postoperative
pulmonary
complications in
patients with OSA as
compared to
neostigmine,
however, the
evidence was very
limited as the studies
were of low to
moderate quality

I

This study confirmed
the efficacy of
sugammadex over

III

Article 2: Comparison of Sugammadex versus Neostigmine Costs and Respiratory Complications in Patients with Obstructive Sleep Apnoea

See below

Not evident

RCT

74 patients in ASA I or
II were

Time to TOF 0.9,
operating room time,
PACU stay,

Time of TOF, operating
room

Quality of evidence is
strong. Literature is
composed of the highest
level of evidence;
systematic review
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randomized into two
groups to receive 2
mg/kg
sugammadex (Group
S) or 0.04 mg/kg
Neostigmine with
0.5mg atropine
(Group N)

postoperative
respiratory
complications, costs
related
to neuromuscular block
reversal and follow-up
and
treatment complications
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time, PACU stay.
Reintubations,
desaturation was
measured. Cost
related to anesthesia
provider.
Cost of reversal drugs.
This study confirmed
the efficacy of
sugammadex over
neostigmine for the
reversal of
rocuronium-induced
neuromuscular
block. Sugammadex
decreases the

neostigmine for the
reversal of
rocuronium-induced
neuromuscular
block. Sugammadex
decreases the
incidence of postoperative respiratory
complications and
related costs in
patients with SA

Article 3: Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: A randomized, controlled study

See below

Not evident

RCT

74 patients received
sugammadex and 77
patients received
usual care
(neostigmine/glycopy
rrolate ). Setting:
Massachusetts
General Hospital,
Boston, MA

Presence of residual
muscle blockade, time
to operating room
discharge-readiness

Zero out of 74
sugammadex patients
and 33 out of 76
(43.4%) usual care
patients had
TOFWatch® SXassessed residual
neuromuscular
blockade at PACU
admission

Incidence of PORC
in PACU

After abdominal
surgery, sugammadex
reversal eliminated
residual
neuromuscular
blockade in the PACU,
and shortened the
time from the start of
study medication
administration to the
time the patient was
ready for discharge
from the operating
room

II

Strength: moderate
sample size at a large
medical hospital.
Established primary and
secondary endpoints
easily identified and
measured. Weakness:
Timing of reversal agent
administration was based
on the providers’ clinical
judgment, allowing room
for variability.

Article 4: Influence of reversal of neuromuscular blockade with sugammadex or neostigmine on postoperative quality of recovery following a single bolus dose of rocuronium: A prospective, randomized, double-blinded,
controlled study

See below

Not evident

RCT

Neostigmine (Group
N, n = 44) ;
sugammadex (Group
S, n = 40) ; Setting:
University Teaching
Hospital from
February to July 2017

Quality of recovery and
recovery rate of Group S
and Group N

The primary endpoint
was the effect of
sugammadex,
compared with
neostigmine, on the
recovery rate in the
physiological domain in
patients who
underwent PPV with
general anesthesia.

Incidence of adverse
events after
sugammadex and
neostigmine

Use of sugammadex
may increase the
quality of
physiological
recovery at early
postoperative
periods, compared
with that of
neostigmine,
following a single

I

Strength: randomized
control trial design,
patient population was
specific in regard to
similar ASA status,
procedure and dosage
given. Weakness: a
minimally invasive surgery
that has a short duration.
Therefore, the study
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The quality of recovery
was assessed using the
Postoperative Quality
Recovery Scale at
15 min and 40 min
after surgery and on
postoperative day 1

bolus dose of
rocuronium in
patients undergoing
PPV with general
anesthesia

outcome may not be
applicable to a larger
population undergoing
different types of
surgeries. Third, the
observation period was
short; the assessment of
PostopQRS was not
performed after
postoperative day 1.

Article 5: The Impact of Sleep Apnea on Postoperative Utilization of Resources and Adverse Outcomes

See below

Not evident

Retrospective
study

Article 6:

Postoperative complications associated with obstructive sleep apnea: time to wake up!

See below

Not evident

Retrospective
Cohort Study

Analyzed hospital
discharge data of
patients who
underwent total hip
or knee arthroplasty
in approximately 400
U.S. Hospitals
between 2006 and
2010. 530,089
entries for patients
undergoing total hip
and knee
arthroplasty. Of
those, 8.4% had a
diagnosis code for SA.

Included: Patients
greater than 18 years
of age, diagnosed
preoperatively with
OSA, and scheduled
to undergo elective
surgery
Excluded:
Patients who were
undergoing surgical
procedures involving

Diagnosis of OSA.
pulmonary and cardiac
complications

The primary variable
was the incidence of
postoperative
complications

Adverse events related
to sleep apnea

Incidence of
postoperative
complications with
and without SA

Pulmonary
complications were
1.86 (95% CI, 1.65–
2.09) times more
likely, and cardiac
complications 1.59
(95% CI, 1.48–1.71)
times more likely to
occur in patients with
SA. In addition, SA
patients were more
likely to receive
ventilatory support,
use more intensive
care, step-down and
telemetry services,
consume more
economic resources
and have longer
lengths of
hospitalization

IV

Strength: L arge volume
of data
Limits: Retrospective
study, unable to control
variables.

The incidence of
postoperative
complications and
related treatments
were compared
between the OSA
patients and the
matched non-OSA
patients

Demographic data
(including gender
and age at the time
of surgery), ASA
physical status, preexisting medical
conditions,
concurrent
medications, type of
surgery and
anesthesia,
postoperative

The incidence of
postoperative
complications in the
OSA patients was
44% vs 28% in the
non-OSA group

IV

Limit: Patients with OSA
were identified by using
ICD-10 codes which is not
all-inclusive of patients
with OSA.
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the upper airway,
including
tonsillectomy,
septoplasty,
uvuloplasty,
uvulopalatoplasty,
uvulopharyngoplasty,
or
uvulopalatopharyngo
plasty

complications and
therapeutic
interventions

Article 7:

Residual curarization and postoperative respiratory complications following laparoscopic sleeve gastrectomy. the effect of reversal agents: Sugammadex vs. neostigmine

See below

Not evident

Article 8:

Postoperative Pulmonary Complications’ Association with Sugammadex versus Neostigmine: A Retrospective Registry Analysis

See below

Not evident

Article 9:

Role of sugammadex in accelerating postoperative discharge: A meta-analysis

Retrospective
study

Retrospective
Study

Patients (179)
undergoing
laparoscopic sleeve
gastrectomy from
July 2012 to July 2013
at Wolfson Medical
Center

Adult patients from
the Vanderbilt
University Medical
Center database who
underwent general
anesthesia
procedures between
January 2010 and July
2019

Compared parameters
included demographic
and anesthetic data,
residual curarization,
oxyhemoglobin
saturation (SpO2) in the
recovery room (PACU),
episodes of SpO2 lower
than 90% in PACU,
unexpected intensive
care (ICU) admissions,
the incidence of
atelectasis and
pneumonia,
reintubation, and
duration of
hospitalization.

Block reversed with
neostigmine or
sugammadex

Incidence of PORC and
residual block

The primary outcome
was postoperative
pulmonary
complications defined
by pneumonia,
prolonged mechanical
ventilation, and/or
unplanned intubation.

An inverse
probability of
treatment weighting
propensity score
analysis approach
was applied to
control for
measured
confounding

With the inherent
limitations of a
retrospective study,
the use of
sugammadex
following
laparoscopic sleeve
gastrectomy showed
no advantage over
neostigmine in terms
of residual
curarization and
respiratory
complications

IV

Limits: retrospective
study, relatively small
sample size.

No difference was
observed on the odds
of postoperative
pulmonary
complications in
patients receiving
sugammadex in
comparison with
neostigmine

IV

Unable to control for the
last train of four causing
missing data for
approximately 40% of
patients.
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Systematic
review/Metaanalysis

See below

Not evident

Article 10:

Sugammadex versus neostigmine for routine reversal of rocuronium block in adult patients: A cost analysis

See below

Not evident

Article 11:

Sugammadex versus neostigmine for reversal of neuromuscular blockade and postoperative pulmonary complications (stronger).

See below

Not evident

Cost analysis

Observational
matched-cohort
study

518 Patients from 6
studies

Data from a local
hospital system
information, metaanalysis of published
studies, and the
general literature was
used to construct
base-case scenarios
and sensitivity
analyses. Analysis
performed from the
perspective of a
single hospital system

Adult patients aged
18 yr or older
undergoing general
anesthesia with an
endotracheal tube
and receiving a
modern steroidal
neuromuscular
blockade agent
(vecuronium or
rocuronium) by bolus
or infusion with
administration of
neostigmine or
sugammadex were
eligible for matching.

Time to discharge after
NMB reversal with
sugammadex or
neostigmine

37

No reversal compared to
Neostigmine/Glyco
reversal compared to
Sugammadex reversal

Exclusion criteria
included age younger
than 18 yr; outpatient
procedure; emergency,
cardiac, liver, or lung
transplantation surgery;
intubation before
operating room arrival;
American Society of
Anesthesiologists.
Physical Status V or VI,
denoting a moribund
patient or a brain-dead
patient undergoing
organ procurement;25
renal failure
documented in
International
Classification of
Diseases, Ninth
Revision/Tenth Revision

Outcome
measurement

Costs associated with
the choice of reversal
drug and differences in
reversal time, the
occurrence of
postoperative nausea
or vomiting (PONV),
and residual blockade
requiring unplanned
postoperative
mechanical ventilation
(UPMV)

Primary outcome was a
composite of
postoperative
pulmonary
complications plausibly
related to residual
neuromuscular
blockade.

Data analysis

Sugammadex was
associated with a
significantly faster
discharge from the
OR to the PACU and
from the PACU to the
surgical ward.

I

Small number of studies
included,

Cost of the drug
compared to OR
time, PACU time,
and cost of
occurrence of
adverse events

Cost analysis
suggested that
reversal with
sugammadex is
preferable to
neostigmine or no
reversal drug

VI

Drug costs can vary
widely and adverse
events were not all
inclusive.

Sugammadex
administration was
associated with a 30%
reduced risk of
pulmonary
complications, 47%
reduced risk of
pneumonia and 55%
reduced risk of
respiratory failure
compared to
neostigmine.

III

Inherent limitations due
to the observational
nature of the study,
which may warrant a
prospective, pragmatic
controlled trial

Rates of (1)
pneumonia, (2)
respiratory failure,
or (3) other major
pulmonary
complications.
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codes or estimated
glomerular filtration rate
less than 30ml/min;
sugammadex used in
combination with
neostigmine;
sugammadex or
neostigmine use with
subsequent redosing of
neuromuscular blockade
agent, suggestive of
temporary
neuromuscular blockade
reversal for
intraoperative
neuromonitoring;
median intraoperative
positive end-expiratory
pressure greater than
10 cm H2O; and
institutional use of
sugammadex for less
than 10% of
neuromuscular blockade
patients.
Article 12:

See below

Article 13:

Kaw, R., Chung, F., Pasupuleti, V., Mehta, J., Gay, P. C., & Hernandez, A. V. (2012). Meta-analysis of the association between obstructive sleep apnoea and postoperative outcome. British journal of
anaesthesia, 109(6), 897–906. https://doi.org/10.1093/bja/aes308

See below

Not evident

Meta-analysis

Thirteen studies were
included in the final
analysis (n=3942)

restricted to cohort or
case–control studies in
adult (>18 yr old)
patients, with
information available on
at least one
postoperative
complication/outcome
in patients with and
without OSA, published
in any language

primary postoperative
outcomes were any
cardiac or respiratory
complications.
Postoperative
respiratory
complications were
characterized as
postoperative
desaturation, acute
respiratory failure
(ARF), and tracheal
reintubation.

The incidence of
postoperative
desaturation,
respiratory failure,
postoperative
cardiac events, and
ICU transfers was
higher in patients
with OSA.

OSA was also
significantly
associated with
higher odds of
desaturation. OSA
was associated with
significantly higher
odds of any
postoperative cardiac
events

I

Weakness: restricted to
cohort or case-control
studies only
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Article 14:

Fernandez-Bustamante, A., Frendl, G., Sprung, J., Kor, D. J., Subramaniam, B., Martinez Ruiz, R., Lee, J. W., Henderson, W. G., Moss, A., Mehdiratta, N., Colwell, M. M., Bartels, K., Kolodzie, K., Giquel, J., &
Vidal Melo, M. F. (2017). Postoperative Pulmonary Complications, Early Mortality, and Hospital Stay Following Noncardiothoracic Surgery: A Multicenter Study by the Perioperative Research Network
Investigators. JAMA surgery, 152(2), 157–166. https://doi.org/10.1001/jamasurg.2016.4065

See below

Not evident

multicenter
prospective
observational
study

7 US academic
institutions. American
Society of
Anesthesiologists
physical status 3
patients who
presented for
noncardiothoracic
surgery requiring 2
hours or more of
general anesthesia
with mechanical
ventilation from May
to November 2014
were included in the
study

noncardiothoracic
surgery requiring 2
hours or more of
general anesthesia with
mechanical ventilation

Predefined PPCs
occurring within the
first 7 postoperative
days were
prospectively
identified. We used
bivariable and logistic
regression analyses to
study the association
of PPCs with
ventilatory and other
perioperative
variables.

Postoperative
pulmonary
complications are
common in patients
with American
Society of
Anesthesiologists
physical status 3,
despite current
protective ventilation
practices. Even mild
PPCs are associated
with increased early
postoperative
mortality, ICU
admission, and length
of stay (ICU and
hospital). Mild
frequent PPCs (eg,
atelectasis and
prolonged oxygen
therapy need)
deserve increased
attention and
intervention for
improving
perioperative
outcomes

3

Weakness: observational
studies
Strength: 7 academic
institutions

Article 15:

Fleisher, L. A., & Linde-Zwirble, W. T. (2014). Incidence, outcome, and attributable resource use associated with pulmonary and cardiac complications after major small and large bowel
procedures. Perioperative Medicine, 3(1). https://doi.org/10.1186/2047-0525-3-7

See below

Not evident

Retrospective
study

45,969 discharges in
patients undergoing
major bowel
procedures

45,969 discharges in
patients undergoing
major bowel
procedures.

Premier database to
determine the
incidence and direct
medical costs related
to pulmonary
complications and
compared it to cardiac
complications in the
same cohort.

current study
demonstrates that
postoperative
pulmonary
complications
represent a
significant source of
morbidity and
incremental cost
after major small
intestinal and colon
surgery and have
greater incidence
and costs than

Postoperative
pulmonary
complications (PPC)
or postoperative
cardiac complications
(PCC) were present in
22% of cases; PPC
alone was most
common (19.0%),
followed by PPC and
PCC (1.8%) and PCC
alone (1.2%). The
incremental cost of
PPC is large

3

Weakness: level of
evidence
Strength: large sample

OUTCOMES OF NMBD REVERSAL IN PATIENTS WITH OSA

40
cardiac
complications alone.
Therefore,
strategies to reduce
the incidence of
these complications
should be targeted
as means of
improving health
and bending the
cost curve in health
care.

($25,498). In
comparison, PCC
alone only added
$7,307 to the total
cost.

Article 16:

Carron, M., Baratto, F., Zarantonello, F., & Ori, C. (2016). Sugammadex for reversal of neuromuscular blockade: A retrospective analysis of clinical outcomes and cost-effectiveness in a single
center. ClinicoEconomics and Outcomes Research, 43. https://doi.org/10.2147/ceor.s100921

See below

Not evident

Article 17:

Retrospective
analysis

five operating rooms
at University Hospital
of Padova, surgical
patients receiving
rocuronium/sugamm
adex

Patients undergoing
general anesthesia with
NMB who received
sugammadex for
“preventive” use were
3% of the total cases
(128 of 4,282 [total
cases]

Impact of sugammadex versus neostigmine/glycopyrrolate on perioperative efficiency

cost-analysis of
NMB management
accompanying the
introduction of a
rocuronium–
neostigmine–
sugammadex
strategy into a
cisatracurium–
neostigmine
regimen was carried
out. To such
purpose, two
periods were
compared: 2011–
2012, without
sugammadex
available; 2013–
2014, with
sugammadex
available. A
subsequent analysis
was performed to
evaluate if
sugammadex
replacing
neostigmine as first
choice reversal drug
is cost-effective.

sugammadex
promotes a rapid
turnover of patients
in the OR, which is
cost-effective and
limits the
disadvantage of its
high cost. Through a
rapid, predictable,
and safe reversal of
rocuronium-induced
NMB, sugammadex
minimizes the risk of
PORC and its
consequences.

3

Weakness: Retrospective
analysis
Strength: large sample
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See below

Not evident

Retrospective
study

Patients admitted to
Houston Methodist
Hospital with a
performed surgical
procedure
Exclusions:
neurosurgical or
cardiac
catheterization
procedure, reversal
agent administration
within the PACU,
extubation prior to
reversal agent
administration or
procedure
completion,
sugammadex reversal
of cisatracurium or
succinylcholine, nonrecorded prePACU/post reversal
agent train-of-four,
zero-minute time
difference from
procedure start or
completion to
reversal agent
administration,
missing endpoint
documentation, and
reversal with both
sugammadex and
neostigmine/glycopyr
rolate

Neuromuscular blocker
agent administration to
exit from OR and PACU
times

41
Cost-effective analysis

The Shapiro–Wilk
normality test
dictated
nonparametric
analysis of
continuous data
with the Wilcoxon
rank-sum test or
Mann–Whitney Utest. The chisquared test or
Fisher’s exact test
was utilized for the
analysis of
categorical
variables.

Sugammadex
administration does
not correlate to
meaningful time
saved in the OR

IV

Limits: small population
of 257, only considered
cost in relation to OR time

Article 1:
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Appendix B
Johns Hopkins Evidence-Based Practice Model
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Appendix C
Otterbein University
IRB Exemption Statement
Conversation between IRB Chair, Dr. Noam Shpancer and Dr. John Chovan, Department of
Nursing Chair.
From: Shpancer, Noam <nshpancer@otterbein.edu>
Sent: Wednesday, October 13, 2021 9:44 AM
To: Chovan, John <jchovan@otterbein.edu>
Subject: Re: IRB and DNP Projects
John: The way I see it, a project is not subject to IRB review unless and until it collects data from
human participants. So, I agree with you that these projects will not need IRB approval until
someone decides to implement them for data collection, at which point that person may apply
for IRB approval.
Thanks, Noam.
From: Chovan, John <jchovan@otterbein.edu>
Sent: Wednesday, October 13, 2021 9:10 AM
To: Shpancer, Noam <nshpancer@otterbein.edu>
Subject: IRB and DNP Projects
Good morning, Noam,
I could use some advice -- maybe a conversation -- about the Doctor of Nursing Practice final
scholarly projects and submitting for IRB approval. The projects parameters from our
accreditors for some of the projects have changed. The list of acceptable projects now includes
the option of writing a plan for a project that is not implemented. So, it can effectively stop at
the proposal stage, and then these projects can be available for a future student to implement
if someone has that interest. I have at least two questions.
1. The IRB Guidelines states "Research means a systematic investigation, including
research development, testing, and evaluation, designed to develop or contribute
to generalizable knowledge." Most of these projects are not intended to develop or
contribute to generalizable knowledge. They are clinical change projects that are
intended to eventually change a clinical practice of health care professionals
(humans) in one identified setting. They have the possibility of contributing to
generalizable knowledge in that each would be an instance of a clinical change that,
if implemented in other places by others, could eventually be generalized. But that
is not the primary intent of the projects. Would they be considered research? I
think they would not.
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2. If indeed they are considered research and should be submitted for review by the
IRB, at what point in the process should IRB approval be obtained? I would think
that although implementation is not part of the initial project, review by IRB would
be helpful to the original team in shaping their project plan. Yet if this proposal is
not going to be implemented, then the approval to move forward would be
moot. But if a second team eventually reads the proposal and wants to implement
it, would they be the ones seeking IRB approval?
If you would prefer that we talk in real time, I am open to that. Or perhaps you could visit one
of our faculty meetings for a discussion?
Thank you.
Best,
John
John D. Chovan, PhD, DNP, RN, CNP, CNS, PMHNP-BC
Associate Professor & Chair, Department of Nursing
Chief Nurse Administrator
Otterbein University
"A comprehensive institution with a strong liberal arts base"
jchovan@otterbein.edu; 614-823-1526, voice; he/him/his
"The world is starved for grace. If we are going to work at restoring fellowship and reaching people, we need grace
now more than ever.”
- Pastor John Swadley, Forest Park Baptist Church, Joplin, Missouri
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RECOMMENDATIONS FOR REVERSAL OF ROCURONIUM
AND VECURONIUM IN PATIENTS AT RISK FOR OR
DIAGNOSED WITH OBSTRUCTIVE SLEEP APNEA

CURRENT PRACTICE

D Neostigmine and glycopyrrolate are used to reverse rocuronium and vecuronium in all patients while
sugammadex is reserved for emergency use.
RECOMMENDATION #1
Every surgical patient should be screened for obstructive sleep apnea with the STOP-Bang screening tool
during the pre--0perative period.

D Many patients with obstmctive sleep apnea remain undiagnosed at the time of surgery.
D It is important to identify these patients early in the perioperative experience so that they can be treated
and monitored appropriately.
RECOMMENDATION #2
A patient identified as at risk for obstructive sleep apnea, as identified by a STOP-Bang score greater than
3, or with a previous diagnosis ofsleep llpnea should be rever;;ed with sugammade.x.

D There is a higher incidence of pulmonary complications for patients with obstructive sleep apnea.
However, there are fewer postoperative complications associated with these patients when reversed with
sugammadex.
D The dosing of sugammadex should follow the manufacturer's guidelines.
RECOMMENDATION #3
Ifpatient scores less than 3 on STOP Bang scale, choice ofrever;;a/ agent shou/d be deferred to clinician
judgement with consideration ofother patient comorbidities.

D Although sugammadex is recognized as the superior reversal agent in the literature, its use should 001 go
uninhibited.

D Patient comorbidities should be evaluated and the risk and benefit of administering sugammadex or
neostigmine should be perfonned on a case-by-ease basis.
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